HIV prevention uptake linked to increased product variety in South Africa

Early data from South Africa indicates that providing multiple HIV prevention modalities, such as the six-monthly injectable, significantly increases user uptake compared to single-option availability. A once-a-month pill is currently entering final-stage clinical trials, potentially further diversifying the prevention landscape. The findings suggest that patient choice is a primary driver for public health efficacy in HIV mitigation.